MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM)

NCT03853616 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Lymphoblastic Leukemia Recurrent
B-cell Lymphoma Recurrent
B-cell Lymphoma Refractory
Chronic Lymphocytic Leukemia Recurrent
Chronic Lymphocytic Leukemia Refractory

Interventions

BIOLOGICAL: MB-CART19.1

Sponsor

Miltenyi Biomedicine GmbH